Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614508 · ClinicalTrials.gov registry record · Phase 1
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02614508: Clinical Trial Phase 1 study, sponsored by Emory University.
NCT02614508 is a Phase 1 study that was terminated before completion, run by Emory University. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02614508, a Phase 1 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of buparlisib when given together with ofatumumab or ibrutinib in treating patients with chronic lymphocytic leukemia that has returned after a period of improvement or does not respond to treatment. Buparlisib and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as ofatumumab, may block cancer growth in different ways by targeting certain cells. Giving buparlisib or ibrutinib and ofatumumab together may work better in treating patients with chronic lymphocytic leukemia.
Primary Outcome
Adverse events and toxicities will be summarized using NCI CTCAE version 4 and based on severity and perceived attribution to study treatment.
Interventions
- DRUG Ibrutinib
- BIOLOGICAL Ofatumumab
- DRUG Buparlisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-08 |
| Phase | Phase 1 |
Why NCT02614508 stopped before completion
NCT02614508 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Ibrutinib is the first listed.
NCT02614508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02614508 about?
NCT02614508 is a clinical study titled "Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia". This phase I trial studies the side effects and best dose of buparlisib when given together with ofatumumab or ibrutinib in treating patients with chronic lymphocytic leukemia that has returned after a period of improvement or does not respond to treatment. Buparlisib and ibrutinib may stop the grow...
What is the current status of trial NCT02614508?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2016-01. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02614508?
The interventions under investigation include: Ibrutinib (DRUG), Ofatumumab (BIOLOGICAL), Buparlisib (DRUG).
Who is sponsoring clinical trial NCT02614508?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02614508's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia